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Abstract
Introduction: Ectopic Cushing`s syndrome (ECS) secondary to neuroendocrine tumours (NETs) of the lung and mediastinum are rarely 
encountered. In this study, we present our experience in Iran on 15 patients with ECS secondary to lung and mediastinal tumours over 
a period of 27 years.
Material and methods: Since 1985, 15 patients with ECS secondary to lung and mediastinal tumours have been diagnosed and prospectively 
followed by the endocrinology team of Taleghani Hospital, Tehran, Iran. The clinical signs and symptoms, laboratory findings, radiological 
features, immunohistochemical characteristics, management strategies and outcome data are here presented.
Results: There were six women and nine men, aged 26–70 years, all presenting with typical features of Cushing’s syndrome. Based on 
histopathologic evaluations, four patients had small cell lung cancer (SCLC) and seven patients had pulmonary NETs, one patient had 
a thymic NET, and one case was diagnosed as a lung tumourlet. The mean ± SD serum cortisol, 24h urine free cortisol and plasma ACTH 
were 47.2 ± 20.5 µg/dL, 2,702 ± 5,439 µg/day, and 220 ± 147 pg/mL, respectively. Pulmonary lesions ranged in diameter from 1.1 to 4 cm 
(mean 1.9 ± 1.1 cm). One patient had a 10 cm mediastinal mass. The duration of follow up in these cases was between one month and 
seven years (mean 29.9 ± 27.5 months). The four patients with SCLC died within three months of diagnosis.
Conclusion: Our data demonstrates the protean clinical and laboratory manifestations of ECS secondary to lung and mediastinal tumours, 
the problems encountered in diagnosis, and the need for a multidisciplinary approach. This study confirms other series from Western 
Europe and North America that, unlike the SCLC patients who show a poor outlook, ECS secondary to lung carcinoids has a more favour-
able prognosis. (Endokrynol Pol 2015; 66 (1): 2–9)
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Streszczenie
Wstep: Ektopowy zespół Cushinga (ectopic Cushing`s syndrome, ECS), który rozwija się u pacjentów mających nowotwory neuroen-
dokrynne (neuroendocrine tumours, NET) śródpiersia lub płuc, jest zaburzeniem rzadko spotykanym. Niniejsza publikacja przedstawia 
doświadczenia autorów z ośrodka w Iranie, którzy w okresie 27 lat prowadzili 15 pacjentów z zespołem Cushinga wtórnym do nowo-
tworów śródpiersia lub płuc.
Materiał i metody: W okresie od 1985 zespół endokrynologów ze szpitala Taleghani Hospital w Teheranie zidentyfikował i prowadził 
w sposób prospektywny 15 pacjentów z objawami ECS uwarunkowanymi obecnością nowotworów śródpiersia lub płuc. Niniejsza 
publikacja przedstawia obraz kliniczny i objawy podmiotowe, wyniki badań laboratoryjnych i radiologicznych oraz badań immuno-
histochemicznych materiału tkankowegoz guzów nowotworowych, a także informacje na temat wdrożonego leczenia i jego wyników.
Wyniki: W badanej grupie znalazło się 6 kobiet i 9 mężczyzn, w wieku 26–70 lat. U wszystkich pacjentów stwierdzono typowe 
cechy kliniczne zespołu Cushinga. Na podstawie badań histopatologicznych wycinków z guzów nowotworowych postawiono 
rozpoznanie drobnokomórkowego raka płuca (SCLC, small cell lung cancer) u 4 pacjentów, neuroendokrynnego nowotworu płu-
ca (NET) bliżej nieokreślonego typu u 7 pacjentów, NET grasicy u jednej osoby oraz rozpoznanie zmiany typu tumorlet w płucu 
u jednej osoby. Średnie stężenie kortyzolu w surowicy ( ± odchylenie standardowe) wyniosło 47,2 ± 20,5 µg/dl, stężenie wolnego 
kortyzolu w moczu ze zbiórki dobowej 2.702 ± 5.439 µg/dobę, a stężenie ACTH w osoczu 220 ± 147 pg/ml. Zmiany nowotworo-
we w płucach miały wielkość od 1,1 do 4 cm (średni wymiar guza 1,9 ± 1,1 cm). Guz śródpiersia (u jednej osoby) miał średnicę 
10 cm. Czas obserwacji wyniósł od 1 miesiąca do 7 lat (średnia 29,9 ± 27,5 miesięcy). Czterech chorych na SCLC zmarło w okresie do 
3 miesięcy od postawienia rozpoznania.











Emediastinal tumours were studied and followed. The 
patients included six women and nine men. All patients 
were examined by the authors and admitted for en-
docrinological evaluation at either the Department of 
Endocrinology of Taleghani General Hospital or Kasra 
Hospital. The surgery and histopathologic evaluations 
were carried out at Taleghani General Hospital, Masih 
Daneshvari and Kasra Hospital. 
All patients underwent routine laboratory evalua-
tion and measurement of serum and 24 hour urinary 
free cortisol (UFC) and basal plasma ACTH concen-
trations. Dexamethasone suppression tests were 
performed according to Liddle’s classic protocols of 
low-dose (2 mg daily for two days) and high-dose 
(8 mg daily for two days) suppression tests, except that 
instead of measuring urinary ketosteroids, UFC was 
measured [15–17]. All the UFC measurements were 
carried out by commercial kits using the RIA (radioim-
munoassay) method. 
Pituitary CT scanning or MRI, abdominal CT scan-
ning, chest radiology and chest CT scanning were 
performed in all cases. CT scans were performed with 
conventional or spiral single slice CT scanners. In all 
of the scans, IV contrast was used. A more sophisti-
cated CT scanner was not available to us. Radionuclide 
octreotide scanning with 111-indium octreotide was 
carried out in only two cases. Inferior petrosal sinus 
sampling (IPSS) was not available to us and, due to 
unavailability of corticotrophin releasing hormone 
(CRH), we could not perform CRH stimulation test for 
our patients. Histopathologic evaluations including 
immunohistochemistry (IHC) studies were interpreted 
by three expert academic pathologists. One patient had 
MEN1 syndrome and has been reported earlier [18]. 
The protocol was approved by the ethics committee of 
the Research Institute for Endocrine Sciences affiliated 
to Shahid Beheshti University of Medical Sciences, 
Tehran, Iran.
Results
Clinical characteristics (Tables I and II)
The patients were six women and nine men, aged 
26–70 years (47.7 ± 14.7 mean ± SD). The duration of 
symptoms was less than one month to 48 months (mean 
Introduction 
Ectopic Cushing`s syndrome (ECS) is defined as en-
dogenous hypersecretion of cortisol secondary to excess 
secretion of ACTH from a non-pituitary origin. The 
syndrome was first described by Brown in 1928 [1]. In 
1963, Liddle et al. defined the condition in more detail 
and suggested possible mechanisms for the pathogen-
esis of the syndrome [2].
ECS constitutes approximately 10% of patients with 
endogenous Cushing’s syndrome (CS) [3-5]. The lung 
is the most prevalent site of tumours leading to ECS. 
Earlier reports indicated that small cell lung carcinoma 
(SCLC) was the main cause of the syndrome, but ac-
cording to more recent studies neuroendocrine tumours 
(NETs) or carcinoids have overtaken SCLC as the most 
frequent tumours causing the syndrome [5–7].
The main concern in the diagnosis and management 
of ECS secondary to lung and mediastinal tumours 
is the heterogeneous clinical presentation, ranging 
from a typical picture of CS to a non-specific picture of 
muscle weakness, electrolyte abnormalities, psychiatric 
manifestations, weight loss, infections and osteoporosis. 
As a result, physicians from different disciplines may 
encounter the syndrome [8, 9].
Due to the rarity of the syndrome, most clinical 
reports in the medical literature present a single case 
or a limited number of cases, and there are few papers 
specifically reviewing clinical and laboratory data in 
a large number of patients suffering from ECS second-
ary to lung tumours [10–14]. 
In this study, we present our experience in 15 pa-
tients with ECS secondary to lung and mediastinal 
tumours who were diagnosed, treated and followed 
up over 27 years at Taleghani and Masih Daneshvari 
University Hospitals affiliated to Shahid Beheshti Uni-
versity of Medical Sciences, Tehran, Iran. This is the first 
study in a Middle Eastern country addressing protean 
manifestations of ECS secondary to lung and mediasti-
nal tumours in a substantial number of patients. 
Material and methods
From 1985, of 110 patients with a diagnosis of Cushing’s 
syndrome, 15 patients with ECS secondary to lung and 
Wnioski: Przedstawione dane wskazują na różnorodność obrazu klinicznego i danych laboratoryjnych u pacjentów z objawami ECS 
w przebiegu choroby nowotworowej śródpiersia lub płuc. Konstelacja ta wymaga więc wielospecjalistycznej opieki już od momentu 
wdrożenia postępowania diagnostycznego. Przedstawione wyniki są zbieżne z danymi z publikacji pochodzących z Europy Zachodniej 
i Stanów Zjednoczonych i wskazują na stosunkowo korzystne rokowanie u pacjentów mających objawy ECS w związku z rakowiakiem 
płuca, w przeciwieństwie do pacjentów mających zmiany typu SCLC. (Endokrynol Pol 2015; 66 (1): 2–9)
Słowa kluczowe: ektopowy zespół Cushinga; śródpiersie; płuco; rakowiak; rak
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12.3 ± 16.4). Based on histopathologic evaluations, four 
patients (cases 1, 10, 11 and 14) had SCLC, and seven 
patients (cases 3, 5–8, 13 and 15) had pulmonary NETs 
(carcinoid tumours). One patient (case 12) had a thymic 
NET. Case 9 was diagnosed as a lung tumourlet. In cases 
2 and 4, we have no tissue diagnosis. In these cases, 
diagnoses were based on clinical grounds, laboratory 
and radiologic data and also follow-up. Patient 2 pre-
sented with mild Cushing’s syndrome in 1986; he was 
a 32-year-old man presenting with muscle weakness 
and a UFC of 220 µg/24 h that was suppressed in Lid-
dle’s low dose suppression test to 143 µg/24 h and in Lid-
dle’s high dose suppression test to 202 µg/24 h. Plasma 
ACTH was 187 pg/mL, and pituitary MRI was normal. 
Evaluations at that time were suggestive of pituitary-
dependent CS, and the patient underwent bilateral 
adrenalectomy (the only available treatment modality 
at that time). The bilateral adrenalectomy showed no 
evidence of adenoma or carcinoma. After surgery, he 
continued to feel unwell but refused regular follow-up. 
He was seen after two years with dyspnoea, and chest 
radiology revealed a large mediastinal mass. Based 
on the low level of UFC suppression in Liddle’s high 
dose suppression test, and finding no macroadenoma 
in pituitary MRI and that high level of plasma ACTH 
and that mediastinal mass in follow-up, we assumed 
the Cushing’s syndrome could have been caused by 
an ectopic ACTH source. The patient was also severely 
hyperpigmented. He refused surgery and died after 
two months because of respiratory failure. Patient 4 was 
a 68-year-old woman presenting with moon face, muscle 
weakness, HTN, severe hypokalaemia (K= 2.1 mEq/L) 
Table I. Clinical data of 15 patients with ectopic Cushing’s syndrome
Tabela I. Dane demograficzne 15 pacjentów z objawami ektopowego zespołu Cushinga
Case no. Sex Age 
(years)
Presenting symptoms Duration 
(months)
Aetiology Follow up 
(months)
Outcome
1 F 62 Fatigability, muscle weakness 3 SCLC 1 Died after two weeks from 
sepsis
2 M 32 Muscle weakness, 
hyperpigmentation, impotence
24 NET? 24 Died two years after 
adrenalectomy due to a huge 
mediastinal mass
3 F 58 Moon face, striae, muscle 
weakness, hypertension
48 Atypical carcinoid 60 Died after five years
4 F 68 Moon face, fatigability, muscle 
weakness, fever, sepsis
2 NET? 1 Died the night before surgery 
because of cardiac arrhythmias
5 M 37 Weight gain, striae, moon face, 
muscle weakness
48 Typical carcinoid 48 Alive without recurrence
6 M 35 Moon face, fatigue, headache, 
striae, weight gain
10 Typical carcinoid 24 Alive without recurrence
7 M 34 Truncal obesity, muscle 
weakness, hypertension
12 Typical carcinoid 60 Alive without recurrence
8 M 43 Moon face, fatigability, muscle 
weakness
2 Typical carcinoid 84 Alive without recurrence
9 F 70 Moon face, fatigability, muscle 
weakness, fever, sepsis
3 NET, tumourlet? 3 Died after three months
10 F 65 Muscle weakness, cough, 
hemoptysis
2 SCLC 2 Died after two months
11 M 40 Fatigability, muscle weakness, 
facial puffiness, anxiety, polyuria, 
polydypsia
1 SCLC 2 died after three months
12 M 41 Typical Cushing’s facies, renal 




36 Died three years after diagnosis




1 alive without recurrence
14 M 61 Jaundice, hypokalaemia, muscle 
weakness
1 SCLC 1 Died after one month
15 M 26 Moon face, fatigability, muscle 
weakness, striae
24 Typical carcinoid 12 Alive with complete recovery












and metabolic alkalosis of two months’ duration. UFC 
was 1,390 µg/24 h that was increased in Liddle’s low 
dose suppression test to 1,540 µg/24 h and in Liddle’s 
high dose suppression test was suppressed to 890 µg/24 
h. Plasma ACTH was 210 pg/mL. Pituitary MRI was 
normal and abdominal CT scan showed bilateral adre-
nal hyperplasia; chest CT scan showed a 2 cm solitary 
pulmonary nodule. Given these figures, we assumed 
Cushing’s syndrome in this patient could not be of pi-
tuitary origin and that there was an ectopic source for 
ACTH. She was referred for surgery but unfortunately 
died the day before it was to be carried out. 
SCLC patients (patients 1, 10, 11, 14)
Two of the patients were female (patients 1 and 10). 
Patient 1 was admitted to CCU because of severe 
hypokalaemia and a refractory arrhythmia. She died 
within two weeks due to sepsis, intractable tachyar-
rhythmias, and heart failure. Tissue diagnosis was made 
post mortem by sampling by a Tru-Cut needle. Patient 
10 presented with severe muscle weakness, weight 
loss and anorexia, and was admitted for evaluation of 
a possible occult carcinoma. Patient 11 was hospitalised 
because of muscle weakness, fatigability, the sudden 
appearance of severe hyperglycaemia, and acute mania. 
She was found to have a mediastinal mass producing 
superior vena caval obstruction. A diagnosis of SCLC 
was obtained following surgical thoracotomy. Patient 
14 presented with jaundice and severe muscle weakness 
and was hospitalised by a gastroenterologist with the 
assumption of liver cirrhosis or metastatic liver disease; 
he also had severe hypokalaemia, diabetes mellitus and 
metabolic alkalosis. He was finally diagnosed as a case 
of ECS secondary to SCLC.
NET patients (patients 3, 5, 6, 7, 8, 9, 12, 13, and 15)
Three patients were female (patients 3, 9, and 13) and 
six patients were male. All patients with ECS due to 
NET had a typical clinical picture of CS with a ‘moon 
face’, truncal obesity, weight gain, muscle weakness, 
fatigability and purple striae, while patients with SCLC 
did not show these classic manifestations of Cushing’s 
syndrome. Patient 12 was a non-classic case of MEN I 
syndrome with Cushing’s syndrome due to a thymic 
neuroendocrine tumour and hyperparathyroidism 
who underwent thoracotomy twice because of tumour 
recurrence, as reported earlier [18]. All patients except 
four (cases 6, 11, 13 and 14) had hypertension, with 
systolic blood pressures ranging from 120 to 190 mm 
Hg and diastolic blood pressures ranging from 80 to 
100 mmHg. Clinical data of the patients is presented 
in Tables I and II.
Laboratory characteristics of patients (Tables III 
and IV)
Basal SC and UFC were high and were unresponsive 
to dexamethasone in all cases. In case 13, basal UFC 
was more than 20 times the normal values. These high 
values are sometimes seen in patients with ECS due 
to elaboration of a significant amount of ACTH from 
the tumours. In seven cases, due to high levels of basal 
UFC and the poor condition of the patients, low-dose 
dexamethasone suppression testing (LDDST) was not 
performed. In response to dexamethasone, only one 
case, number 6, showed 90% suppression during the 
HDDST. This suppression after dexamethasone has 
been reported in 21% of patients and has resulted in 
an erroneous diagnosis of pituitary-dependent CS 
and incorrect therapeutic strategies such as TSS [6]. 
In seven cases, a paradoxical increase in UFC was 
observed. Mean and SD for morning serum cortisol 
was 47.2 ± 20.5 µg/dL. The value for UFC at basal state 
and after low dose (LD) and high dose (HD) DST were 
2,702 ± 5,439, 1,687 ± 1,960 and 2,182 ± 4,552 µg/24 h 
respectively.
Plasma ACTH was elevated in all cases, ranging from 
110 to 579 pg/mL (220 ± 147 pg/mL). Serum potassium 
was low in all cases, ranging from 1.8 to 3.4 mmol/L 
(2.5 ± 0.6). Fasting blood glucose was 119–370 mg/dL 
(206 ± 80). Indeed, seven patients had overt diabetes and 
were under treatment with oral agents or insulin. The 
frequency of overt diabetes was higher in our patients 
Table II. Clinical features of 15 patients with ectopic 
Cushing’s syndrome
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compared to the NIH report, which may be due to 
longer duration of the disease. Diabetes disappeared 
in all patients with NET who were successfully treated. 
Arterial blood gases were evaluated in 13 patients, 
showing metabolic alkalosis in all cases. The labora-
tory data is summarised in Table III. The differences in 
laboratory findings between SCLC patients and NET 
patients are shown in Table IV. 
Imaging characteristics
Plain chest radiology was positive in all cases except 
cases 2, 14 and 15. The pulmonary lesions ranged in size 
from 1.1 to 4 cm (1.9 ± 1.1 cm). In ten cases, the diameter 
was 2 cm or less. Patient 12 had a 10 cm mediastinal 
mass. Lesions were interpreted as non-significant in 
three patients. In one patient, the lesion was misinter-
preted as fibrosis, because he worked in a mine. 
CT scanning of the chest defined the lesions in more 
detail and the surgical decision was based on the find-
ings of the chest CT. In cases 3, 10, 11 and 14, mediastinal 
lymph nodes were apparent. 
Pituitary CT scanning or MRI was carried out in all 
cases except 1, 11 and 14 because the pulmonary lesion 
was prominent and the patient’s general condition was 
so poor that the procedure was contra-indicated. In all 
cases, pituitary gland was reported as normal except in 
case 13 that showed a 5mm pituitary lesion. 
Abdominal CT scanning for the evaluation of adre-
nal glands was carried out in 12 cases, demonstrating 
bilateral hyperplasia in seven cases and being reported 
as normal in five cases. 
A radionuclide octreotide scan was performed in 
cases 12 and 13: it was positive in the first and negative 
in the second. 
Histopathologic characteristics (Tables I and V)
Tissue for histopathologic evaluation was available in 
13 cases. In case 1, the tissue was obtained through 
a closed needle biopsy after the patient’s death. In 
patient 14, the tissue was obtained through a bone 
marrow biopsy. In the remaining cases, the tissue was 
obtained through a standard thoracotomy. The size of 
the tumours varied between 1 and 2.5 cm in all cases 
except case 9, who had a tumourlet, and case 12 who 
had a 10 cm mediastinal mass. 
Four cases were diagnosed as SCLC, six cases were 
diagnosed as NETG1 (typical carcinoid) of the lung, 
one case was diagnosed as a tumourlet, and three 
cases as NETG2 (atypical carcinoids). In patients with 
NETG1 (typical carcinoids), microscopic evaluation 
revealed no necrosis with mitotic features less than 
2 per high power field; the Ki-67 index was less than 4% 
in these cases. In cases 3, 12 and 13, whose diagnoses 
were NETG2 (atypical carcinoids), the Ki-67 was 20%, 
30% and 7% respectively. It is worth noting that in case 
12 the resected tumour at first surgery showed less ag-
gressive behaviour with a Ki-67 of 7%, but showed more 
aggressive behaviour at second surgery with a Ki-67 
of 30%. IHC staining was performed in eight cases: all 
cases showed positivity for chromogranin and ACTH. 
The interesting finding was that the number of cells 
which were positive for ACTH was considerably lower 
in cases with NETG2 (atypical carcinoids). Tables 1 and 
4 show the histopathologic and IHC characteristics of 
the patients.
Medical therapy
In eight cases, ketoconazole was advised either before 
surgery to ameliorate the severe hypercortisolic state or 
to control Cushing’s syndrome after surgery. The dose 
of ketoconazole was between 200 and 600 mg/day. No 
Table III. Laboratory findings of 15 patients with ectopic 
Cushing’s syndrome
Tabela III. Wyniki badań laboratoryjnych u 15 pacjentów 
z objawami ektopowego zespołu Cushinga



















Hypokalaemia [K < 3.5 mmol/L]
Hypokalaemia [K < 3 mmol/L]
Metabolic alkalosis

















Table IV. Comparison of laboratory findings in patients with 
SCLC and NET
Tabela IV. Porównanie wyników badań laboratoryjnych 
u pacjentów mających nowotwory typu SCLC i pacjentów 
z rozpoznaniem NET
NET SCLC
Serum cortisol 39.30 ± 8.84 52.75 ± 14.02
UFC 1,739 ± 898 723 ± 228
Plasma ACTH 148 ± 50 300 ± 129
Serum potassium 2.51 ± 0.58 2.25 ± 0.11
Fasting blood glucose 182 ± 55 299 ± 55












special adverse effect necessitating discontinuation of 
treatment was observed.
Surgical therapy
Two patients with SCLC and nine patients with NET 
underwent surgery, which was uneventful. The surgi-
cal technique was a postero-lateral thoracotomy under 
general anaesthesia with a double-lumen endotracheal 
tube. Cases 11 and 12 underwent surgery for mediasti-
nal mass. Extensive lymph node dissection was not per-
formed, and in all cases lymph nodes that were larger 
than normal in the surgeon’s opinion were removed.
Outcome and follow up
SCLC patients
The four cases with SCLC died 1–3 months after diag-
nosis despite treatment with ketoconazole and other 
supportive measures.
NET patients
Case 3 who was diagnosed as NETG2 (atypical carci-
noid) was alive for five years despite the recurrence of 
CS. She relapsed one year after surgery, but was fairly 
well-controlled on ketoconazole after her second surgery. 
Case 4 died the night before surgery, presumably due to 
electrolyte imbalance and a cardiac arrhythmia. Patient 
9, who had a tumourlet, died three months after surgery 
because of pulmonary tuberculosis and non-compliance 
on follow-up; the patient was an Afghan immigrant in 
a poor condition due to the severity of hypercortisolism, 
infection and malnutrition. Case 12 had a thymic NET and 
MEN1 and died after three years despite two mediastinal 
operations because of the relapse of his CS and reap-
pearance of the tumour. The other patients (cases 5–8, 13 
and 15) with NETG1 (typical carcinoids) are all still alive 
without any symptoms or signs of CS or recurrence of the 
tumour, and are in complete remission.
The criterion for remission was two UFC measure-
ments within normal limits after surgery, and then a 
UFC measurement every six months. The duration of 
follow up in these cases was between one month and 
seven years (29.9 ± 27.5 months). 
Discussion
The data presented here clearly demonstrates the 
protean clinical and laboratory manifestations of ECS 
secondary to lung and mediastinal tumours. The prob-
lems encountered in diagnosis, the need for a multidis-
ciplinary approach, and the different outcomes of the 
patients are also highlighted. 
As mentioned earlier, ECS secondary to lung and 
mediastinal tumours is rare and there are only a limited 
number of papers reviewing the full spectrum of dis-
ease. Of the papers focusing on lung and mediastinal 
tumours leading to CS, Pass et al. from the NIH reported 
on 14 cases [14], the paper from Amer et al. from the UK 
on 19 cases [12], Sharger et al. from the Massachusetts 
General Hospital reported on seven cases [13], and Deb 
et al. [11] from Mayo Clinic discussed the clinical and 
laboratory data of 23 patients. 
The recognition of different lung tumours leading 
to ECS has changed substantially in recent decades. In 
1969, Liddle et al. reported that 52 out of 57 patients 
with lung tumour and ECS had SCLC [2, 9], while re-
cent studies have shown that NETs or carcinoids of the 
lungs and mediastinum are the most common tumours 
leading to ECS and comprise around one-third of the 
cases. SCLC is the causative tumour in 20% of cases. As 
a result, more than half of the cases of ECS originate 
from tumours within the thorax [5, 6, 19].
Table V. Immunohistochemical characteristics of the patients
Tabela V. Wyniki badań immunohistochemicznych nowotworów
Case no. Diagnosis Chromogranin Synaptophysin Cytokeratin ACTH Ki-67
frequency intensity
3 NETG2 (atypical carcinoid) + + + + +++ 20%
5 NETG1 (typical carcinoid) + + + + +++ 4%
6 NETG1 (typical carcinoid) + + + +++ ++ 3%
7 NETG1 (typical carcinoid) + + + +++ ++ 4%
8 NETG1 (typical carcinoid) + + + + +++ 4%
12 NETG2 (atypical carcinoid) + + + ++ ++ 30%
13 NETG2 (atypical carcinoid) + + + ++ ++ 7%
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The clinical symptoms of patients with SCLC 
differed substantially from those with a carcinoid tu-
mour. Patients with SCLC presented with non-specific 
symptoms, such as weight loss, muscle weakness and 
electrolyte abnormalities, and presented to physicians 
from different specialties. This paraneoplastic or acute 
EAS contrasts with classic EAS that is present ab initio 
with a classic presentation of Cushing’s syndrome [4, 
20]. The duration of the disease was less than one month 
in our patients. Symptoms of pulmonary problems 
were seen only in case 11, who presented with superior 
vena cava (SVC) obstruction. In other patients, severe 
hypokalaemia and muscle weakness were the most 
important symptoms which led to diagnosis. 
Clearly, ECS should be kept in mind in the differ-
ential diagnosis of severe hypokalaemia and muscle 
weakness. All patients died within three months after 
diagnosis. It seems that both severe hypercortisolism 
and its direct consequences including hypokalaemia 
and its related cardiac arrhythmias, hyperglycaemia 
and severe infection (sepsis), and rapid progression of 
the tumour and its complications such as SVC or hepatic 
metastases, contribute to this poor prognosis.
Patients with ECS secondary to NETs were sympto-
matically similar to patients with pituitary-dependent 
CS and diagnosed much earlier. The diagnoses in these 
cases were due to prominent symptoms of CS, clinical 
suspicion of ECS, and also positive radiological findings 
of the lung in the majority of cases. The unavailability 
of IPSS was a main problem in differentiating pituitary-
dependent CS from ECS. Thus, as mentioned earlier, 
case 2 underwent bilateral adrenalectomy and the 
mediastinal tumour that was not seen at first evalua-
tion became apparent after two years, a phenomenon 
referred to as ‘covert Cushing’s syndrome’ [4, 5]. How-
ever, the diagnosis is not easy in all cases and in many 
patients the underlying neoplasm may be so small that 
it escapes detection for a long time; hence, there may 
be a substantial delay in terms of years in establishing 
the correct diagnosis [21, 22].
The duration of the disease in patients with SCLC 
was 1–3 months, which underlines the rapid course 
and severity of the disease. In contrast, the duration 
of the disease for patients with NET was much longer; 
between one month and four years, which is in ac-
cordance with a more favourable course of the disease.
It seems that thymic carcinoids secreting ACTH 
show a more aggressive course and present at a younger 
age, and it has been proposed to call them ‘neuroendo-
crine carcinomas’ instead of carcinoids. Thymic NETs 
may be associated with MEN-I and this possibility 
should be considered [18, 23].
Plain chest radiology was positive in all cases ex-
cept 2, 14 and 15. In the study by Deb et al. [11], 13 of 
23 patients (57%) had positive radiology. In the study 
by Pass et al. [14], and the study by Limper et al. [24], 
plain radiology revealed a tumour only in 33% (five 
of 15 patients in each study). In the St. Bartholomew’s 
Hospital series, positive plain radiology findings were 
reported in five of 12 patients with bronchial carcinoids 
and five of seven patients with SCLC [5] hence, it seems 
that our patients might have had larger tumours or 
it might have been because of the larger number of 
patients with SCLC in our series. Chest CT scanning 
was positive in all cases except case 2. The lesions were 
better illustrated on chest CT scans. In three patients 
with tumours of less than 2 cm, plain radiology findings 
were interpreted as fibrosis or a non-significant finding. 
Radiologic misinterpretation which resulted from the 
small size of the tumours led to delays in chest surgery. 
Our impression is that any pulmonary lesion should 
be interpreted as significant in patients suspected of 
ECS. Contrary to the findings of Sharger et al. and 
Pass et al. [13, 14] that reported almost 50% lymph 
node metastases in their patients with pulmonary 
carcinoid, we could find lymph node metastasis in 
only four cases. These four cases had either SCLC or 
NETG2 (atypical carcinoids). This is in accordance 
with the benign course of NETG1 (typical carcinoids). 
The 5 mm lesion in the pituitary MRI of the patient 
13 was apparently an incidentaloma. Incidental findings 
in pituitary imaging have led to erroneous diagnoses 
of pituitary-dependent CS and implementation of un-
toward treatment strategies such as transsphenoidal 
surgery (TSS) [22]. Indeed, a significant percentage of 
patients with EAS (up to 50%) have undergone inap-
propriate TSS before the correct diagnosis [6, 11, 12, 
14, 20, 24–27]. Some patients have even undergone 
a second TSS [25, 26] or received pituitary radiotherapy 
with the assumption of persistent Cushing’s disease 
[6, 11, 20, 26]. A few patients have been reported to have 
undergone unilateral adrenalectomy, either as the first 
treatment of Cushing’s syndrome with the assump-
tion of adrenal origin of hypercortisolism, or after an 
unsuccessful TSS [6, 20]. One patient has been reported 
to have undergone TSS twice, pituitary radiotherapy, 
and eventually adrenalectomy [26]. This points to dif-
ficulties in diagnosing the true source of the Cushing’s 
syndrome. 
Bilateral adrenal hyperplasia was seen in seven 
cases. This could be either due to duration of the disease 
or sensitivity of the imaging machines used.
The major limitation in this study was the unavail-
ability of IPSS and also CRH for a more accurate dif-
ferentiation between EAS and pituitary-dependent CS. 
However, while IPSS and CRH testing was not avail-
able to us, the diagnosis was based on strong clinical 
grounds, firm laboratory findings of hypercortisolism, 












the exclusion of other causes of CS, histopathologic find-
ings, IHC of tumours showing positivity for ACTH and 
chromogranin, and clinical and biochemical improve-
ment after resection of the tumour. 
Thus, while these more sophisticated techniques 
can accelerate the diagnosis of such patients, their 
absence does not preclude accurate diagnosis and ef-
fective therapy, and this point is especially relevant in 
the delivery of medical care in the developing world.
Conclusion
We have presented the clinical and laboratory picture 
and also the management strategy of ECS secondary 
to lung and thymic tumours from a tertiary centre in 
Iran. According to the data provided, it is obvious that 
the disease is rare and if not properly managed can be 
lethal. When ECS develops in patients with SCLC, the 
clinical picture of CS does not develop, and muscle 
weakness and hypokalaemia can be the most prominent 
features. In cases due to pulmonary NET, the clinical pic-
ture of CS in usually present. The responsible tumour 
is usually small and can easily be missed. 
Our study confirms other series from Western 
Europe and North America showing that, unlike ECS 
secondary to SCLC which is highly lethal, the prognosis 
in ECS secondary to NET is more favourable provided 
that the patients are diagnosed and surgically managed 
early in their course. In the case of a relapse, medical 
treatment can be effective for many years. 
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